While individuals taking semaglutide can still contract COVID-19, they had a 33% lower chance of dying from the sickness, according to a study published by the Journal of the American College of Cardiology at the end of August.
The studies also show that semaglutide can reduce a patient’s risk of serious heart events such as heart attacks and strokes.
